MARKET

BOLD

BOLD

BOUNDLESS BIO INC
NASDAQ
1.200
+0.070
+6.19%
After Hours: 1.240 +0.04 +3.33% 19:02 04/13 EDT
OPEN
1.120
PREV CLOSE
1.130
HIGH
1.230
LOW
1.120
VOLUME
193.70K
TURNOVER
--
52 WEEK HIGH
1.780
52 WEEK LOW
0.9612
MARKET CAP
26.89M
P/E (TTM)
-0.4611
1D
5D
1M
3M
1Y
5Y
1D
Boundless Bio Terminates Major Long-Term San Diego Lease
TipRanks · 6h ago
Weekly Report: what happened at BOLD last week (0406-0410)?
Weekly Report · 19h ago
Weekly Report: what happened at BOLD last week (0330-0403)?
Weekly Report · 04/06 09:12
Weekly Report: what happened at BOLD last week (0323-0327)?
Weekly Report · 03/30 09:12
Weekly Report: what happened at BOLD last week (0316-0320)?
Weekly Report · 03/23 09:11
Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader
Seeking Alpha · 03/20 07:25
Boundless Bio to present oral kinesin degrader program at AACR Annual Meeting 2026
Reuters · 03/17 20:52
BOUNDLESS BIO ANNOUNCES UPCOMING PRESENTATION OF ORAL KINESIN DEGRADER PROGRAM AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2026
Reuters · 03/17 20:52
More
About BOLD
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.

Webull offers Boundless Bio Inc stock information, including NASDAQ: BOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BOLD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BOLD stock methods without spending real money on the virtual paper trading platform.